NUBURU Poised to Finalize Strategic Acquisition and Prepare the Adoption of Advanced Technology, Artificial Intelligence & Robotics Initiatives as It Awaits Italian Government ‘Golden Power' Approval NUBURU, Inc. (NYSE:BURU), a leader in high-power blue laser technology, announced today that it has filed with the Securities and Exchange Commission a Form S-3 Registration statement for $100 million. This strategic move is designed to provide the company with the necessary capital to facilitate the ongoing acquisition plan and successfully relaunch its Blue Laser technology business unit. As reaffirmed in the latest communications, NUBURU aims at completing the purchase of defense and secur

WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) ("Coeptis" or the "Company"), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious diseases, and Z Squared Inc. ("Z Squared"), a Dogecoin mining company, today announced they have entered into a definitive merger agreement for a business combination that will result in Z Squared becoming a wholly-owned subsidiary of Coeptis. Under the terms of the merger agreement, a wholly-owned subsidiary of Coeptis will merge with and into Z Squared and the holders of the outstanding Z Squared shares will receive equity in

WEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with U.S.-based NexGenAI Solutions Group (https://nexgenai.io) and Indian technology firm Ishvara Tech Consulting LLP. The new facility, operated by Ishvara Tech Consulting LLP, will serve as a collaborative space for the NexGenAI Affiliates Group (https://nexgenaiaffiliates.io) fostering advancements in artificial intelligence (AI), blockchain technologies, digital transformation, and robotic soluti

Shareholder Update: Strengthening Business Lines Through Innovative Applications in Blue Laser Technology, Artificial Intelligence, Robotics, and Fintech Solutions NUBURU, Inc. (NYSE:BURU), a leader in high-power and high-brightness industrial blue laser technology, is excited to provide a comprehensive update to its shareholders regarding its newly formulated business model canvas, which encompasses two synergistic key business lines. Blue Laser Technology & Product Development. NUBURU is revitalizing its blue-laser technology business unit by collaborating closely with the previous management team to develop a new strategic plan aimed specifically at addressing the defense sector's nee

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep r

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network "NexGen" and NUBURU, Inc. "NUBURU" (NYSE:BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS' strategic position in technology and Artificial Intelligence and NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model entering defense

NUBURU, Inc. (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology announced its strategic partnership with COEPTIS' NexGenAI Affiliates Network (NASDAQ:COEP), an innovative provider of artificial intelligence and robotics solutions. This collaboration is a pivotal component of NUBURU's comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company's business model. The Transformation Plan, by leveraging the existing know-how regarding blue-laser technology and additional expertise to be brought by the new management team, is specifically designed to l

WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS' NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate NexGenAI's advanced digital marketing solutions into the highly anticipated ValuSocial platform, harnessing the power of Verus Coin and its scalable Public Blockchains as a Service (PBaaS). The innovative ValuSocial platfo

WEXFORD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) --  COEPTIS, Inc. (NASDAQ:COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partnership between COEPTIS' NexGenAI Affiliates Network and MarketLeverage, a leading digital advertising firm and affiliate network. This collaboration aims to redefine affiliate marketing by integrating cutting-edge AI technology with performance-based strategies. With MarketLeverage's extensive industry expertise and NexGenAI Affiliates Network's innovative AI-powered platform, this collaboration will empower affiliates, brands, and marketers with advanced automation, da

WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents. COEP Venture Group aims to identify, invest in, and support high-potential startups shaping the future of automation, intelligent systems, and AI-driven enterprise solutions.

SC 13G/A - Coeptis Therapeutics Holdings, Inc. (0001759186) (Subject)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

10-Q - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B3 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

8-K - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

424B4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

EFFECT - Coeptis Therapeutics Holdings, Inc. (0001759186) (Filer)

Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infections, as well as preclinical programs for hematologic and solid tumors WEXFORD, Pa., Aug. 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. ("Deverra") related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generat

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

4 - Coeptis Therapeutics Holdings, Inc. (0001759186) (Issuer)

Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa., Aug. 30, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Colleen Delaney, MD, MSc, has been appointed Chief Scientific and Medical Officer of Coeptis following the completion of an exclusive rights agreement with Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs.

15-year accounting and finance career spans several sectors including life sciences and underscores financial leadership abilities WEXFORD, Pa., May 17, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) ("Coeptis" or the "Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced today the appointment of Brian Cogley, MBA, to the position of Chief Financial Officer (CFO) effective immediately. Mr. Cogley brings 15 years of accounting and finance experience to Coeptis, having previously held positions of increasing authority at two "Big 4" accounting firms and served on the management teams of multiple companies in diverse in